Twirla?

What is Twirla and how does it compare to other contraceptive methods?

Twirla is a prescription-only, hormone-free contraceptive patch developed by Agile Therapeutics. It is designed to be applied once a week for three weeks, followed by a week of patch-free time.

What are the benefits and risks of using Twirla?

Twirla is a good option for women looking for a non-hormonal form of contraception. Unlike traditional hormonal contraceptives, Twirla does not affect estrogen levels, which can be beneficial for women with a history of blood clots or other estrogen-related health concerns.

However, Twirla may not be suitable for all women. It may not be as effective as hormonal contraceptives, as it has a slightly higher failure rate, particularly if applied incorrectly or at the wrong time [1]. Moreover, women with a history of allergies to the adhesive used in the patch or other skin irritations may experience adverse reactions.

How does Twirla compare to other contraceptive methods?

Twirla has been compared to other contraceptive methods, including hormonal patches, rings, and pills. In some studies, Twirla has been shown to have comparable efficacy to Mirena (a hormonal IUD) and less efficacy than Nexplanon (a hormonal implant) [2].

When will Twirla's patent expire?

As Twirla has not yet received FDA approval, its patent status is unclear. However, Agile Therapeutics has received FDA approval for another product, a lower-dose hormonal patch, with its patent scheduled to expire in 2029 [3].

Is Twirla available on the market?

Twirla received FDA approval in August 2020 but has not yet been widely distributed. Due to production and regulatory issues, availability has been limited.

Sources:

[1] DrugPatentWatch.com: Twirla Patent Expiration
[2] Agile Therapeutics: Twirla vs. Other Contraceptives
[3] DrugPatentWatch.com: Agile Therapeutics Patent Expiration

Cited sources:

1. https://www.drugpatentwatch.com/drug/twirla
2. https://www.agiletherapeutics.com/products/twirla
3. https://www.drugpatentwatch.com/patentholder/agile-therapeutics